A Study of Safety Tolerability and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma

Investigation of Safety of Investigational Medications in Liver Cancer Treatment

Recruiting
18 years - 100 years
All
Phase N/A
1 Location

Brief description of study.

The purpose of this study is to see if two investigational drugs, called MEDI4736 and tremelimumab (either drug alone or in combination) are safe in treating adult subjects with liver cancer (hepatocellular carcinoma) that cannot be removed by surgery (unresectable).

Detailed description of study

The purpose of this study is to see if two investigational drugs, called MEDI4736 and tremelimumab are safe in treating adult subjects with liver cancer that cannot be removed by surgery.

Participants will be compensated for their participation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: liver cancer,hepatocellular carcinoma
  • Age: 18 years - 100 years
  • Gender: All

Inclusion Criteria
In order to be eligible to take part in this trial, patients must meet the following criteria:

  • 18 years or older
  • Confirmed diagnosis of unresectable hepatocellular carcinoma with or without concomitant viral hepatits B or hepatitis C infection

For a full list of participation criteria, please visit clinicaltrials.gov.

Updated on 19 Feb 2024. Study ID: 1601354641

This study investigates the safety of two investigational medications in treating adults with liver cancer that cannot be removed by surgery. The medications are being tested alone and in combination to evaluate their effects on liver cancer, also known as hepatocellular carcinoma.

Participants in this study will undergo treatment with either one of the investigational medications or a combination of both. The study will monitor the safety and effects of these treatments on the participants.

  • Who can participate: Adults aged 18 years or older with liver cancer that cannot be removed by surgery are eligible. Participants may have a diagnosis with or without viral hepatitis B or C infection.
  • Study details: Participants will receive treatment with investigational medications. The study will monitor the safety of these medications. If applicable, a placebo will be used to compare against the investigational treatments.

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact label
Race
Ethnicity
Other language

Default Content Message Here